Raymond James Reiterates Outperform Rating for Myriad Genetics (NASDAQ:MYGN)
Raymond James reaffirmed their outperform rating on shares of Myriad Genetics (NASDAQ:MYGN – Free Report) in a research report report published on Tuesday,Benzinga reports. They currently have a $19.00 price objective on the stock, down from their previous price objective of $27.00. Other research analysts have also recently issued reports about the company. Bank of […]
Raymond James reaffirmed their outperform rating on shares of Myriad Genetics (NASDAQ:MYGN – Free Report) in a research report report published on Tuesday,Benzinga reports. They currently have a $19.00 price objective on the stock, down from their previous price objective of $27.00. Other research analysts have also recently issued reports about the company. Bank of […]
